Skip to main content
. 2017 Mar 22;8(29):46969–46980. doi: 10.18632/oncotarget.16443

Table 2. Meta-analysis results of the association between rs895819 and cancer risk.

Variables Na G vs. A GG vs. AA AG vs. AA GG+AG vs. AA GG vs.AG+AA
OR (95% CI) I2 (%) OR (95% CI) I2 (%) OR (95% CI) I2(%) OR (95% CI) I2 (%) OR (95% CI) I2(%)
Overall 28 1.03 (0.97,1.10)b 56.4 1.12 (0.97,1.29)b 52.2 0.99 (0.91,1.06)b 42.6 1.01 (0.94,1.09)b 49.7 1.11 (0.97,1.26)b 49.6
Ethnicity
Asians 22 1.05 (0.97,1.13)b 55.9 1.13 (0.95,1.34)b 54.2 1.02 (0.93,1.11)b 36.6 1.04 (0.95,1.13)b 44.9 1.10 (0.93,1.30)b 54.9
Caucasians 6 0.94 (0.88,1.01) 48.7 0.98 (0.83,1.15) 36.8 0.87 (0.79,0.96) 43.0 0.89 (0.81,0.98) 49.0 1.05 (0.90,1.22) 23.1
Cancer type
BC 9 0.93 (0.87,0.99) 0.0 0.90 (0.78,1.04) 0.0 0.97 (0.84,1.11)b 50.3 0.91 (0.83,0.99) 33.7 0.92 (0.80,1.05) 0.0
CRC 5 1.19 (1.08,1.32) 9.9 1.58 (1.28,1.96) 0.0 0.98 (0.85,1.14) 29.3 1.11 (0.97,1.27) 23.0 1.58 (1.29,1.93) 0.0
LC 2 0.95 (0.82,1.11) 0.0 1.02 (0.69,1.51) 0.0 0.90 (0.74,1.09) 0.0 0.91 (0.76,1.10) 0.0 1.07 (0.73,1.57) 0.0
GC 5 1.06 (0.87,1.29)b 75.7 1.08 (0.68,1.70)b 74.7 1.06 (0.86,1.31)b 60.8 1.08 (0.85,1.36)b 70.9 1.05 (0.71,1.56)b 68.6
ESCC 2 1.00 (0.89,1.12) 25.4 0.95 (0.72,1.26) 54.1 1.03 (0.89,1.19) 0.0 1.02 (0.88,1.17) 0.0 0.94 (0.72,1.24) 52.4
Others 5 1.09 (0.84,1.41)b 74.3 1.35 (0.73,2.49)b 69.0 0.99 (0.75,1.31)b 59.5 1.05 (0.77,1.43)b 69.4 1.35 (0.80,2.28)b 60.5
Source of controls
PB 10 1.04 (0.94,1.15)b 55.9 1.05 (0.91,1.21) 22.2 1.06 (0.90,1.24)b 63.7 1.07 (0.92,1.24)b 63.8 1.03 (0.90,1.18) 15.2
HB 18 1.03 (0.94,1.11)b 59.0 1.12 (0.91,1.37)b 61.7 0.94 (0.88,1.01) 21.4 0.99 (0.90,1.08)b 40.5 1.14 (0.94,1.37)b 58.9

a: number of studies; b: calculating based on random-effects model; BC: breast cancer; CRC: colorectal cancer; LC: lung cancer; GC: gastric cancer; ESCC: esophageal squamous cell carcinoma.